Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare
Conference
PT. RICHMOND, Calif., Dec. 7 /PRNewswire/ -- Transcept Pharmaceuticals,
Inc. today announced that Glenn A. Oclassen, President & Chief Executive
Officer, will participate in an expert panel on "Drug Development in a Changed
Environment" at the RBC Capital Markets 2007 Healthcare Conference at the
Westin New York Hotel at Times Square on Thursday, December 13, 2007 at 10:00
AM Eastern Time.
The multi-company panel will be moderated by Ken Trbovich, Vice President,
Capital Markets at RBC, and will be available at the following link via
webcast: http://www.wsw.com/webcast/rbc84/panel24.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to provide
additional uses and enhanced clinical benefits for existing active agents. The
lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low
dose sublingual formulation of zolpidem that is currently in late phase 3
clinical trials for the treatment of insomnia in patients who awaken in the
middle of the night and have difficulty returning to sleep. Another product
being developed by Transcept is TO-2060, a novel, fixed-dose combination of
olanzapine and ondansetron for the treatment of dopamine associated
psychiatric disorders. TO-2060 is currently the subject of an initial proof of
concept trial in the treatment of alcohol use disorder. For more information,
please visit the company's website at: http://www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill Investors / Media
Director of Communications Stephanie Carrington / Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
mgill@transcept.com scarrington@theruthgroup.com
jrando@theruthgroup.com
SOURCE Transcept Pharmaceuticals, Inc.
Michael Gill, Director of Communications of Transcept Pharmaceuticals, Inc.,
+1-510-215-3575, mgill@transcept.com; or Investors, Stephanie Carrington,
+1-646-536-7017, scarrington@theruthgroup.com, or Media, Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group for Transcept
Pharmaceuticals, Inc.
